Occudo Quantitative Strategies’s BioMarin Pharmaceuticals BMRN Stock Holding History

Occudo Quantitative Strategies’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-13,478	Closed	-$1.12M	–	1184
2022 Q2	$1.12M	Buy	13,478 +7,735	+135%	+$616K	0.09%	349
2022 Q1	$443K	Buy	+5,743	New	+$481K	0.04%	696
2021 Q4	–	Sell	-2,994	Closed	-$231K	–	1073
2021 Q3	$231K	Buy	+2,994	New	+$236K	0.03%	813
2021 Q2	–	Sell	-6,119	Closed	-$462K	–	880
2021 Q1	$462K	Buy	+6,119	New	+$500K	0.1%	354

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Occudo Quantitative Strategies's BMRN Position: Q3 2022 in Review

Occudo Quantitative Strategies sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2022, closing a stake of 13,478 shares — an estimated $1.12M sold.

Occudo Quantitative Strategies first reported a position in BMRN in Q1 2021 and held it in 4 quarters. The position peaked at $1.12M in Q2 2022. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

Occudo Quantitative Strategies reported no remaining BioMarin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Occudo Quantitative Strategies sold 13,478 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $1.12M.
Occudo Quantitative Strategies first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 4 quarters.
Occudo Quantitative Strategies's BioMarin Pharmaceuticals position peaked at $1.12M in Q2 2022.
551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q3 2022, filed 14 Nov 2022.